



## Medication Audit Criteria and Guidelines

### Acamprosate (CAMPRAL®)

PEFC Approved: April 2021

#### Indications

- Maintenance of abstinence from alcohol in patients with alcohol use disorder who are abstinent at treatment initiation

#### Contraindications

- Hypersensitivity to acamprosate calcium or any of its components
- Severe renal impairment (creatinine clearance  $\leq$  30 mL/min)

#### Warnings and Precautions

- Use of acamprosate does not eliminate or diminish withdrawal symptoms
- Renal impairment
- Suicidality
- Central nervous system depression

#### Adverse Reactions

Side Effects Which Require Medical Attention

- Accidental injury
- Weakness/decreased energy
- Pain
- Anorexia
- Diarrhea
- Anxiety
- Depression
- Dizziness
- Dry mouth
- Insomnia
- Pruritus/paresthesia
- Sweating

## Drug Interactions of Major Significance

See: [Indiana Univ Drug Interaction Table](#)

See: Lexicomp, Micromedex for more information

## Special Populations

- Pediatrics/Adolescents
  - ▶ Safety and efficacy have not been established in children younger than 18 years.
- Renal
  - ▶ Dose reduction required for moderate renal impairment (creatinine clearance 30-50 mL/min).
  - ▶ Contraindicated in severe renal impairment (creatinine clearance ≤ 30mL/min).
- Pregnancy and Breastfeeding
  - ▶ Review product-specific labeling. Consider risks/benefits in reviewing medication-specific labeling.

## Patient Monitoring Parameters

- Comprehensive Metabolic Panel (renal function) – baseline and as clinically indicated
- Weight – baseline and as clinically indicated
- Pregnancy test – baseline and as clinically indicated
- Emergence of worsening depression, suicidal ideation, or suicidal behavior

## Dosing

- See HHSC Psychiatric Drug Formulary for dosage guidelines.
- Exceptions to maximum dosage must be justified as per medication rule.